Trial Profile

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Glioblastoma; Male breast cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms LEAP-005
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

15 Nov 2024 Status changed from active, no longer recruiting to completed.
19 Sep 2024 Planned End Date changed from 20 Dec 2024 to 31 Oct 2024.
19 Sep 2024 Planned primary completion date changed from 20 Dec 2024 to 31 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com